Exploring the Use of Diabetic Medications for Non-Diabetic Conditions: A Comprehensive Literature Review
DOI:
https://doi.org/10.47672/ajhmn.1586Keywords:
GLP 1 Agonists, SGLT 2 Inhibitors, Cardiovascular Benefits, Nephroprotection, ObesityAbstract
Purpose: Currently, a significant portion of the US population has been impacted by diabetes, and alongside it, heart failure, chronic kidney disease (CKD), obesity, and non-alcoholic fatty liver disease (NAFLD) rates are on the rise. Recent research has highlighted the potential of antidiabetic medications to extend beyond diabetes management. This literature review is aimed at exploring the evolving roles of GLP-1 receptor agonists, SGLT2 inhibitors, and thiazolidinediones. It specifically investigates their applications in cardiovascular disease, chronic kidney disease (CKD), obesity, polycystic ovarian syndrome (PCOS), and NAFLD. As a novel therapeutic approach, their application could reshape treatment strategies for interconnected metabolic disorders, offering a new horizon in patient care.
Methodology: We conducted a comprehensive search of PubMed and Google Scholar for English-language studies published in the United States and Canada between January 1st, 2013, and August 31st, 2023 focusing on trials involving GLP-1RA, SGLT-2i, and thiazolidinediones therapy.
Findings: In our study, GLP-1 receptor agonists emerged as multifaceted pharmaceutical agents, showcasing improvements in cardiovascular disease outcomes, nephroprotective effects, substantial efficacy in obesity management, and promising prospects in addressing non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS). Additionally, thiazolidinediones displayed effectiveness in the management of non-alcoholic steatohepatitis (NASH), while metformin exhibited notable benefits in PCOS management. Furthermore, Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors demonstrated remarkable advancements, particularly in terms of cardiovascular and renal benefits. Our findings emphasize the diverse and evolving applications of diabetic medications in addressing a wide range of chronic medical conditions, ultimately leading to enhanced patient care and improved outcomes.
Recommendations: We recommend that healthcare practitioners carefully consider the expanded utility of these medications beyond their conventional diabetic indications and explore their integration into treatment strategies for the indicated medical conditions. This should be done while thoughtfully weighing the associated risks and benefits to ensure the most effective and safe patient care possible.
Downloads
References
Adult Obesity Facts | Overweight & Obesity | CDC. (n.d.). Retrieved September 1, 2023, from https://www.cdc.gov/obesity/data/adult.html.
Alruwaili, H., Dehestani, B., & Le Roux, C. W. (2021). Clinical Impact of Liraglutide as a Treatment of Obesity. Clinical Pharmacology: Advances and Applications, 13, 53. https://doi.org/10.2147/CPAA.S276085
Azziz, R. (2018). Polycystic Ovary Syndrome. Obstetrics and Gynecology, 132(2), 321–336. https://doi.org/10.1097/AOG.0000000000002698
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014). Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet. Diabetes & Endocrinology, 2(5), 369–384. https://doi.org/10.1016/S2213-8587(13)70208-0
Beulens, J. W. J., Rutters, F., Rydén, L., Schnell, O., Mellbin, L., Hart, H. E., & Vos, R. C. (2019). Risk and management of pre-diabetes. European Journal of Preventive Cardiology, 26(2_suppl), 47–54. https://doi.org/10.1177/2047487319880041
Blazina, I., & Selph, S. (2019). Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. Systematic Reviews, 8(1). https://doi.org/10.1186/S13643-019-1200-8
Bonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018). Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 103(10), 3773–3782. https://doi.org/10.1210/JC.2018-00824
Butler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., Ponikowski, P., Shah, S. J., Senni, M., Vedin, O., Verma, S., Peil, B., Pocock, S. J., Zannad, F., Packer, M., & Anker, S. D. (2022). Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 145(3), 184–193. https://doi.org/10.1161/CIRCULATIONAHA.121.057812
Butler, J., Usman, M. S., Khan, M. S., Greene, S. J., Friede, T., Vaduganathan, M., Filippatos, G., Coats, A. J. S., & Anker, S. D. (2020). Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Failure, 7(6), 3298–3309. https://doi.org/10.1002/EHF2.13169
Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 - American College of Cardiology. (n.d.). Retrieved September 1, 2023, from https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2018/11/08/23/09/DECLARE-TIMI-58
Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi, J. L., Kalyani, R. R., Kosiborod, M., Magwire, M., Morris, P. B., Neumiller, J. J., & Sperling, L. S. (2020). 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology, 76(9), 1117–1145. https://doi.org/10.1016/J.JACC.2020.05.037
Devin, J. K., Nian, H., Celedonio, J. E., Wright, P., & Brown, N. J. (2020). Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. The Journal of Clinical Endocrinology and Metabolism, 105(1), 136. https://doi.org/10.1210/CLINEM/DGZ028
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., McCoy, R. G., Mentz, R. J., & Piña, I. L. (2019). Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation, 140(7), E294–E324. https://doi.org/10.1161/CIR.0000000000000691
Essah, P. A., Arrowood, J. A., Cheang, K. I., Adawadkar, S. S., Stovall, D. W., & Nestler, J. E. (2011). Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. Fertility and Sterility, 96(2). https://doi.org/10.1016/J.FERTNSTERT.2011.05.091
Filippatos, G., Butler, J., Farmakis, D., Zannad, F., Ofstad, A. P., Ferreira, J. P., Green, J. B., Rosenstock, J., Schnaidt, S., Brueckmann, M., Pocock, S. J., Packer, M., & Anker, S. D. (2022). Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Circulation, 146(9), 676–686. https://doi.org/10.1161/CIRCULATIONAHA.122.059785
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., Mcguire, D. K., Wilding, J. P. H., Ruff, C. T., Nicolau, J. C., Gause-Nilsson, I. A. M., Fredriksson, M., Langkilde, A. M., Sabatine, M. S., & Wiviott, S. D. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction: Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, 139(22), 2516–2527. https://doi.org/10.1161/CIRCULATIONAHA.119.039996
Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014). Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Research and Clinical Practice, 103(3), 373–381. https://doi.org/10.1016/J.DIABRES.2013.12.052
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., Xavier, D., Atisso, C. M., Dyal, L., Hall, S., Rao-Melacini, P., Wong, G., Avezum, A., Basile, J., Chung, N., … Zigrang, W. (2019). Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet, 394(10193), 131–138. https://doi.org/10.1016/S0140-6736(19)31150-X
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A.-M., & Wheeler, D. C. (2020). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 383(15), 1436–1446. https://doi.org/10.1056/NEJMOA2024816
Heerspink, H., Karasik, A., … M. T.-T. lancet D. &, & 2020, undefined. (n.d.). Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Thelancet.Com. Retrieved July 31, 2023, from https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30384-5/fulltext.
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., Maggioni, A. P., Marso, S. P., Öhman, P., Pagidipati, N. J., Poulter, N., Ramachandran, A., Zinman, B., & Hernandez, A. F. (2017). Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 377(13), 1228–1239. https://doi.org/10.1056/NEJMOA1612917/SUPPL_FILE/NEJMOA1612917_DISCLOSURES.PDF
Honigberg, M. C., Chang, L. S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020). Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. JAMA Cardiology, 5(10), 1182. https://doi.org/10.1001/JAMACARDIO.2020.1966
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017). An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology, Diabetes, and Obesity, 24(1), 73–79. https://doi.org/10.1097/MED.0000000000000311
Jia, X., Alam, M., Ye, Y., Bajaj, M., & Birnbaum, Y. (2018). GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovascular Drugs and Therapy, 32(1), 65–72. https://doi.org/10.1007/S10557-018-6773-2
Kelly, M. S., Lewis, J., Rao, H., Carter, J., & Portillo, I. (2022). Effects of GLP-1 Receptor Agonists on Cardiovascular Outcomes Effects of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease: A in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Systematic Review and Meta-Analysis Systematic Review and Meta-Analysis. https://doi.org/10.1002/phar.2737
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., Kosiborod, M. N., & Butler, J. (2020a). Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation, 142(12), 1205–1218. https://doi.org/10.1161/CIRCULATIONAHA.120.045888
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., Kosiborod, M. N., & Butler, J. (2020b). Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. Circulation, 142(12), 1205–1218. https://doi.org/10.1161/CIRCULATIONAHA.120.045888
Klein, K., Pate, V., Assimon, M., … T. S.-D., & 2022, undefined. (n.d.). Antihyperglycemic medication use among US adults with hemodialysis-dependent kidney disease and comorbid diabetes. Am Diabetes Assoc. Retrieved June 23, 2023, from https://diabetesjournals.org/care/article-abstract/45/9/126/147253.
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes and Endocrinology, 7(10), 776–785. https://doi.org/10.1016/S2213-8587(19)30249-9
Latif, W., Lambrinos, K. J., & Rodriguez, R. (2023). Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs). StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK572151/
Levin, P. A., Nguyen, H., Wittbrodt, E. T., & Kim, S. C. (2017). Glucagon-like peptide-1 receptor agonists: A systematic review of comparative effectiveness research. Diabetes, Metabolic Syndrome and Obesity, 10, 123–139. https://doi.org/10.2147/DMSO.S130834
Liver - American Liver Foundation. (n.d.). Retrieved September 1, 2023, from https://liverfoundation.org/.
Lopaschuk, G. D., & Verma, S. (2020). Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC. Basic to Translational Science, 5(6), 632–644. https://doi.org/10.1016/J.JACBTS.2020.02.004
Mancini, G. B. J., O’Meara, E., Zieroth, S., Bernier, M., Cheng, A. Y. Y., Cherney, D. Z. I., Connelly, K. A., Ezekowitz, J., Goldenberg, R. M., Leiter, L. A., Nesrallah, G., Paty, B. W., Piché, M. E., Senior, P., Sharma, A., Verma, S., Woo, V., Darras, P., Grégoire, J., … Zimmerman, D. (2022). 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology, 38(8), 1153–1167. https://doi.org/10.1016/J.CJCA.2022.04.029
Mancini, G., O’Meara, E., Zieroth, S., … M. B.-C. J. of, & 2022, undefined. (n.d.). 2022 Canadian Cardiovascular Society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults. Elsevier. Retrieved July 31, 2023, from https://www.sciencedirect.com/science/article/pii/S0828282X2200335X.
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., Boer, R. A. de, Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., … Langkilde, A.-M. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. Https://Doi.Org/10.1056/NEJMoa1911303, 381(21), 1995–2008. https://doi.org/10.1056/NEJMOA1911303
Mehta, A., Marso, S. P., & Neeland, I. J. (2017). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3. https://doi.org/10.1002/OSP4.84
Menne, J., Dumann, E., Haller, H., & Schmidt, B. M. W. (2019). Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Medicine, 16(12). https://doi.org/10.1371/JOURNAL.PMED.1002983
Mikhail, N. (2018). Cardiovascular Effects of Liraglutide. Current Hypertension Reviews, 15(1), 64–69. https://doi.org/10.2174/1573402114666180507152620
Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab, 18(3), 203–216. https://doi.org/10.1111/dom.12591
Nauck, M. A., Tornøe, K., Rasmussen, S., Treppendahl, M. B., & Marso, S. P. (2018). Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diabetes & Vascular Disease Research, 15(5), 465. https://doi.org/10.1177/1479164118783935
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017). Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 377(7), 644–657. https://doi.org/10.1056/nejmoa1611925
Niafar, M., Pourafkari, L., Porhomayon, J., & Nader, N. (2016). A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Archives of Gynecology and Obstetrics, 293(3), 509–515. https://doi.org/10.1007/S00404-015-3976-7
Nouraei, H., Leiter, L. A., Tan, M. K., Langer, A., Teoh, H., Cheng, A. Y. Y., Wald, R., Connelly, K. A., Goodman, S. G., & Yan, A. T. (2021). Glycemic Control and Cardiovascular Risk Factor Management in Adults With Type 2 Diabetes With and Without Chronic Kidney Disease Before Sodium-Glucose Cotransporter Protein 2 Inhibitors: Insights From the Diabetes Mellitus Status in Canada Survey. Canadian Journal of Diabetes, 45(8), 743–749. https://doi.org/10.1016/J.JCJD.2021.02.003
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., Komajda, M., Miller, A., Pehrson, S., Teerlink, J. R., Brueckmann, M., Jamal, W., Zeller, C., Schnaidt, S., & Zannad, F. (2021). Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation, 143(4), 326–336. https://doi.org/10.1161/CIRCULATIONAHA.120.051783
Pandey, A. K., Dhingra, N. K., Hibino, M., Gupta, V., & Verma, S. (2022). Sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta-analysis. ESC Heart Failure, 9(2), 942–946. https://doi.org/10.1002/EHF2.13805
PCOS (Polycystic Ovary Syndrome) and Diabetes | CDC. (n.d.). Retrieved September 1, 2023, from https://www.cdc.gov/diabetes/basics/pcos.html.
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., & Wilding, J. P. H. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMOA1411892
Pitt, B., Bhatt, D. L., Szarek, M., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Ezekowitz, J. A., Sun, F., Davies, M. J., … Steg, P. G. (2023). Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF. JACC: Heart Failure, 11(8), 879–889. https://doi.org/10.1016/J.JCHF.2023.05.026
Pittampalli, S., Upadyayula, S., Hema, ;, Mekala, M., & Lippmann, S. (2018). Risks vs Benefits for SGLT2 Inhibitor Medications. Federal Practitioner, 35(7), 45. /pmc/articles/PMC6368009/
Rasquin, L. I., Anastasopoulou, C., & Mayrin, J. V. (2022). Polycystic Ovarian Disease. Encyclopedia of Genetics, Genomics, Proteomics and Informatics, 1528–1528. https://doi.org/10.1007/978-1-4020-6754-9_13178
Rocha, A. L., Oliveira, F. R., Azevedo, R. C., Silva, V. A., Peres, T. M., Candido, A. L., Gomes, K. B., & Reis, F. M. (2019). Recent advances in the understanding and management of polycystic ovary syndrome. In F1000Research (Vol. 8). F1000 Research Ltd. https://doi.org/10.12688/f1000research.15318.1
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., Rosenstock, J., & Gerstein, H. C. (2021). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. The Lancet Diabetes and Endocrinology, 9(10), 653–662. https://doi.org/10.1016/S2213-8587(21)00203-5
Solomon, J., Festa, M., … Y. C.-P. &, & 2022, undefined. (n.d.). Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease. Elsevier. Retrieved July 31, 2023, from https://www.sciencedirect.com/science/article/pii/S0163725822002248.
Szarek, M., Bhatt, D. L., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., Lund, L. H., Komajda, M., Testani, J. M., Wilcox, C. S., Ponikowski, P., Lopes, R. D., Banks, P., Tesfaye, E., Ezekowitz, J. A., … Pitt, B. (2021). Effect of sotagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure. Annals of Internal Medicine, 174(8), 1065–1072. https://doi.org/10.7326/M21-0651
Thomas, M. C. (2017). The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. Diabetes & Metabolism, 43, 2S20-2S27. https://doi.org/10.1016/S1262-3636(17)30069-1
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., & Perkovic, V. (2019). Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes, Obesity & Metabolism, 21(5), 1237–1250. https://doi.org/10.1111/DOM.13648
Rasmussen, S., & Bain, S. C. (2023). Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney International. https://doi.org/10.1016/j.kint.2022.12.028
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018). Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The Lancet. Diabetes & Endocrinology, 6(8), 605–617. https://doi.org/10.1016/S2213-8587(18)30104-9
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Zimmermann, A. G., Woodward, B., & Botros, F. T. (2019). Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7). Diabetes, Obesity and Metabolism, 21(6), 1493–1497. https://doi.org/10.1111/DOM.13668
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D. (2022a). SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet (London, England), 400(10354), 757–767. https://doi.org/10.1016/S0140-6736(22)01429-5
Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D. (2022b). SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet (London, England), 400(10354), 757–767. https://doi.org/10.1016/S0140-6736(22)01429-5
Vallon, V., & Thomson, S. C. (2017). Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia, 60(2), 215–225. https://doi.org/10.1007/S00125-016-4157-3
Vogt, L. (2021). Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 384(4), 388–390. https://doi.org/10.1056/nejmc2032809
Weir, M. R., Pollak, M., Friedman, D., Barisoni, L., Falk, R., Gipson, D., Lipkowitz, M., Ojo, A., Chirieac, M., Xu, C., Fortier, A., Egbuna, O., Bun-nage, M., & Chertow, G. (2022). National Kidney Foundation 2022 Spring Clinical Meeting Abstracts. American Journal of Kidney Diseases, 79(5), 768. https://doi.org/10.1053/j.ajkd.2022.02.002
Wilcox, T., De Block, C., Schwartzbard, A. Z., & Newman, J. D. (2020). Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. Journal of the American College of Cardiology, 75(16), 1956–1974. https://doi.org/10.1016/J.JACC.2020.02.056
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMOA2032183
Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022). Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney International Reports, 7(11), 2546–2547. https://doi.org/10.1016/j.ekir.2022.08.016
Younossi, Z. M. (2019). Non-alcoholic fatty liver disease - A global public health perspective. Journal of Hepatology, 70(3), 531–544. https://doi.org/10.1016/J.JHEP.2018.10.033
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022). GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Research and Clinical Practice, 41(2), 136–149. https://doi.org/10.23876/J.KRCP.22.001
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., Cannon, C. P., Capuano, G., Chu, P.-L., de Zeeuw, D., Greene, T., Levin., A., Pollock, C., Wheeler, D. C., Yavin, Y., Mahaffey, K. W. (2019). Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380(24),2295–2306.https://doi.org/10.1056/NEJMOA1811744/SUPPL_FILE/NEJMOA1811744_DATA-SHARING.PDF
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rosemary O. Iriowen , Temituoyo F. Edema , Victor O. Dike , Taiwo I. Ogundipe , Ifeoluwa O. Oluwatowoju , Bright C. Nwatamole , Ogochukwu A. Okonkwo , Okelue E. Okobi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work’s authorship and initial publication in this journal.
